Cumulus Neuroscience and Muse by Interaxon said on July 6 that they have integrated Muse’s at‑home EEG into Cumulus’s NeuLogiq® multi‑modal clinical platform to add brain‑based sleep measurement for central nervous system (CNS) trials.

The companies framed the integration as a way to capture sleep EEG—brain electrical activity recorded during sleep—outside the clinic. Cumulus described NeuLogiq® as its multi‑modal platform for collecting remote trial data and said the Muse system will provide validated overnight EEG recordings to that platform.

Sleep EEG allows measurement of sleep stages (for example, NREM and REM) and other electrophysiological features that sponsors and investigators use as objective sleep endpoints or exploratory biomarkers in CNS studies. The companies said the integrated capability is intended for use in clinical trials that require objective, at‑home sleep data.

The announcement originates from statements issued in Belfast, Dublin and Toronto. The companies did not list specific trials, sponsors, or a public rollout timeline in the release.

Both firms positioned the move as expanding options for remote physiological monitoring in brain‑health research. The companies said they will provide the integrated sleep EEG capability to clinical customers through the NeuLogiq® platform.

Photo credit: content-media.pamedia.io

Tags: sleep EEG, at-home EEG, clinical trials, Muse, NeuLogiq

Topics: Wearable neurotech, EEG & neuro-sensing headsets, Sleep technology